In summary, this large population-based study shows an increase in the incidence of diabetes among breast cancer survivors after systemic therapy, especially the patients with later pathological stages, more lymph node metastasis, negative hormone receptor expression, and positive HER2 expression. The gene discussed is ERBB2; the disease is breast cancer.